Literature DB >> 2554717

Prediction of 'high-risk' cervical papillomavirus infection by biopsy morphology.

D W Franquemont1, B E Ward, W A Andersen, C P Crum.   

Abstract

Certain human papillomavirus (HPV) types (such as type 16) have been linked to high-grade precancers and invasive carcinomas of the cervix. However, the accuracy with which morphologic characteristics will predict the presence and type of HPV infection is controversial. Three pathologists independently classified 102 consecutive cervical biopsies with the use of specific criteria and correlated their findings with the presence of HPV 11, 16, and 18 RNA sequences by in situ hybridization. Based on the presence and distribution of nuclear atypia, abnormal mitotic figures, and koilocytosis, biopsies were classified into borderline condyloma, condyloma, borderline cervical intraepithelial neoplasia (CIN) with koilocytotic atypia (CINK), and CIN. Two or more observers agreed on the diagnosis in 96% of cases. HPV 16-related sequences alone were detected in 0% of borderline condylomata, 17% of flat condylomata, 43% of borderline CINK, 67% of CINK, and 77% of CIN lesions. Other HPVs, including those producing signals with more than one probe, were present in 0, 50, 14, 9, and 0% of these lesions, respectively. The authors data suggest that consistent identification of HPV-related cervical disease requires the presence of specific cytologic changes. In the authors' series, when HPV-related disease is present, CIN is the most common lesion and most (71%) contain HPV 16-related nucleic acids. Thus, a high proportion (88%) of histologic abnormalities associated with HPV-16 could be distinguished as CIN by morphologic characteristics alone, and this distinction could be made by most observers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554717     DOI: 10.1093/ajcp/92.5.577

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  In situ hybridization for human papillomavirus as a method of predicting the evolution of cervical intraepithelial neoplasia.

Authors:  A Pich; E Margaria; B Ghiringhello; R Navone
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

2.  In situ human papillomavirus (HPV) genotyping of cervical intraepithelial neoplasia in South African and British patients: evidence for putative HPV integration in vivo.

Authors:  K Cooper; C S Herrington; A K Graham; M F Evans; J O McGee
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

3.  Detection of transforming gene regions of human papillomavirus type 16 in cervical dysplasias by the polymerase chain reaction.

Authors:  J Czeglédy; M Evander; L Veres; L Gergely; G Wadell
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

4.  Analysis of transforming gene regions of human papillomavirus type 16 in normal cervical smears.

Authors:  J Czeglédy; I Batár; M Evander; L Gergely; G Wadell
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

5.  Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma.

Authors:  Eduardo Cambruzzi; Cláudio Galleano Zettler; Cláudio Osmar Pereira Alexandre
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

6.  Human papillomavirus type 18 and intraepithelial lesions of the cervix.

Authors:  C M McLachlin; J E Tate; J C Zitz; E E Sheets; C P Crum
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

Review 7.  Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis.

Authors:  C P Crum; S Barber; J K Roche
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

Review 8.  Replication and assembly of human papillomaviruses.

Authors:  M J Conway; C Meyers
Journal:  J Dent Res       Date:  2009-04       Impact factor: 6.116

Review 9.  Cervical Pre-cancers: Biopsy and Immunohistochemistry.

Authors:  Meherbano Kamal
Journal:  Cytojournal       Date:  2022-06-14       Impact factor: 2.345

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.